There have been recent attempts to stratify patients into “high-risk” and “low-risk” populations, using potential prognostic biomarkers, such as clinical tumor (T) stage, tumor cytogenetics (e.g., monosomy 3), and immunohistochemistry (BAP-1 mutation testing) [11,12], and gene expression profile (GEP) testing [13]. Here, BAP1 is linked to neoplasm.